Derived psychoactive cannabis products (DPCPs) have rapidly become available in retail outlets across the U.S. since the 2018 U.S. Agriculture Improvement Act (also known as the Farm Bill) implicitly legalized the product and sale of these products. DPCPs are regulated as “hemp”; there are currently no federal regulations on product safety or marketing.

This month, Dr. Matthew Rossheim presented information on recent shifts in the U.S. cannabis markets and their implications, the harms from using derived psychoactive cannabis products, and regulations effective in mitigating these harms. Access the recording of Dr. Rossheim’s presentation and a link to his slides here.